BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
0.00 (0.00%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.55 - 3.60
Open     -
Vol / Avg. 0.00/515,648.00
Mkt cap 117.36M
P/E 22.42
Div/yield     -
EPS 0.09
Shares 55.88M
Beta 0.50
Inst. own 50%
Mar 15, 2018
Q4 2017 BioDelivery Sciences International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Dec 7, 2017
BioDelivery Sciences International Inc Annual Shareholders Meeting
Nov 28, 2017
BioDelivery Sciences International Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -106.20% -431.87%
Operating margin -89.27% -411.26%
EBITD margin - -402.21%
Return on average assets -51.66% -86.58%
Return on average equity -212.47% -957.27%
Employees 99 -
CDP Score - -


4131 Parklake Ave Ste 225
RALEIGH, NC 27612-2390
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr., M.D. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Scott Plesha President
Bio & Compensation  - Reuters
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 63
Bio & Compensation  - Reuters
Peter L. Ginsberg Vice President - Business Development
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Timothy C. Tyson Director
Age: 62
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 55
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 72
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters